Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation.
Miyanaga A, Shimizu K, Noro R, Seike M, Kitamura K, Kosaihira S, Minegishi Y, Shukuya T, Yoshimura A, Kawamoto M, Tsuchiya S, Hagiwara K, Soda M, Takeuchi K, Yamamoto N, Mano H, Ishikawa Y, Gemma A.
Miyanaga A, et al. Among authors: kitamura k.
BMC Cancer. 2013 May 29;13:262. doi: 10.1186/1471-2407-13-262.
BMC Cancer. 2013.
PMID: 23714228
Free PMC article.